Atopic dermatitis: dupilumab profile consistent with phase 3 trials

  • Olesen CM & al.
  • J Eur Acad Dermatol Venereol
  • 8 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Data from a tertiary hospital suggest that dupilumab (Dupixent) had comparable effectiveness and safety for moderate to severe atopic dermatitis, as in phase 3 randomized clinical trials (RCTs).

Why this matters

  • Real-world data are needed to confirm the effectiveness and safety of therapies approved on the basis of phase 3 trials.

Key results

  • Dupilumab was associated with a 72.4% improvement in Eczema Area and Severity Index (EASI) score at 1 month, and a 76.7% improvement at 3 months (P<.001 for both>
  • Dupilumab was also associated with improved itch (P<.001 sleep dermatology life quality index score serum total ige and lactate dehydrogenase p at months.>
  • Reductions in EASI score were correlated with LDH at 3 months (P=.003).
  • 1 patient (2.3%) discontinued because of adverse effects.
  • 18.4% of patients experienced conjunctivitis during 3-month follow-up.

Study design

  • 43 patients with moderate to severe atopic dermatitis treated with dupilumab were included.
  • Funding: None.

Limitations

  • Small patient sample size.
  • No comparator group.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit